Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 110, showing 5 Applications out of 547 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/25/06/03   ZHR-001
    Physiological and Biomarker Monitoring: Enhancing Vital Signs and Biomarkers Algorithm of Binah.AI in the Kenyan Population   
Principal Investigator(s)
1. Borna Achieng Nyaoke
Site(s) in Kenya
Zuri Health Medical Centre
 
View

17.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
View

18.

ECCT/25/05/13   IVI CCV 002
    A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region   
Principal Investigator(s)
1. Walter Jaoko
Site(s) in Kenya
KAVI - Institute of Clinical Research, University of Nairobi
 
View

19.

ECCT/25/05/06   Hibiscus 2 - Site 254
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county)
 
View

20.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
View